Briviact (Brivaracetam) Patent Expiration, LOE Window & CMS Spending

Briviact (Brivaracetam) by Ucb: FDA Orange Book core substance LOE 2026-02-21 (last listed 2030-04-09), 7 AB generics, $463.4M 2024 CMS Part D & Medicaid spend, and 20 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorUcb
FDA Application & PathwayN205836 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2026-02-21
Last Listed Patent or Exclusivity Date2030-04-09
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$463.4M
2024 Medicare Part D Spend$219.8M
2024 Medicaid Spend$243.6M
Reported Wholesale Price Change (CA SB 17)20 WAC filings (max 18.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.